All Photos(1)

Documents

Y0001031

Lamotrigine for peak identification

Name: Lamotrigine for peak identification
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Lamotrigine, 6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diamine, GI 267119X

Sign Into View Organizational & Contract Pricing

All Photos(1)

About This Item

Empirical Formula (Hill Notation):

C₉H₇Cl₂N₅

CAS Number:

84057-84-1

Molecular Weight:

256.09

MDL number:

MFCD00865333

UNSPSC Code:

41116107

PubChem Substance ID:

329831228

NACRES:

NA.24

grade

pharmaceutical primary standard

API family

lamotrigine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

Nc1nnc(c(N)n1)-c2cccc(Cl)c2Cl

InChI

1S/C9H7Cl2N5/c10-5-3-1-2-4(6(5)11)7-8(12)14-9(13)16-15-7/h1-3H,(H4,12,13,14,16)

InChI key

PYZRQGJRPPTADH-UHFFFAOYSA-N

Gene Information

human ... SCN10A(6336) , SCN11A(11280) , SCN1A(6323) , SCN2A(6326) , SCN3A(6328) , SCN4A(6329) , SCN5A(6331) , SCN7A(6332) , SCN8A(6334) , SCN9A(6335)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Analytical Reference Standards

Pharmacopeia & Metrological Institute Standards

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Lamotrigine for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Anticonvulsant.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.

Description

Pricing

1356778

1356790

1356789

PHR1368

PHR1392

Lamotrigine, Pharmaceutical Secondary Standard; Certified Reference Material

BP1097

Lamotrigine, British Pharmacopoeia (BP) Reference Standard

BP1098

Lamotrigine impurity standard, British Pharmacopoeia (BP) Reference Standard

PHR8729

PHR8730

Pictograms

GHS06

Signal Word

Danger

Hazard Statements

H301

Precautionary Statements

P264 - P270 - P301 + P310 - P405 - P501

Hazard Classifications

Acute Tox. 3 Oral

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Modulation of the antidepressant-like effects of sustained administration of carisbamate and lamotrigine on monoaminergic systems: electrophysiological studies in the rat brain.

Stacey Shim et al.

The Journal of pharmacology and experimental therapeutics, 347(2), 487-496 (2013-08-30)

Carisbamate and lamotrigine are anticonvulsants that act on neuronal voltage-gated sodium channels. Carisbamate has shown antidepressant-like effects in animal models of depression, and lamotrigine is a mood stabilizer with a therapeutic effect in depressive episodes of patients with bipolar disorder.

Functional and structural evaluation of lamotrigine treatment in rat models of acute and chronic ocular hypertension.

Shai Sandalon et al.

Experimental eye research, 115, 47-56 (2013-07-03)

Voltage gated sodium channels (Nav), are proposed mediators of neuronal damage in ischemic and excitotoxicity disease models. We evaluated the neuroprotective effects of lamotrigine, a Nav blocker, in the acute and chronic rat ocular hypertension models. Additionally, expression of the

Beneficial effects of mood stabilizers lithium, valproate and lamotrigine in experimental stroke models.

Zhi-fei Wang et al.

Acta pharmacologica Sinica, 32(12), 1433-1445 (2011-11-08)

The mood stabilizers lithium, valproate and lamotrigine are traditionally used to treat bipolar disorder. However, accumulating evidence suggests that these drugs have broad neuroprotective properties and may therefore be promising therapeutic agents for the treatment of neurodegenerative diseases, including stroke.

Enhancing depression mechanisms in midbrain dopamine neurons achieves homeostatic resilience.

Allyson K Friedman et al.

Science (New York, N.Y.), 344(6181), 313-319 (2014-04-20)

Typical therapies try to reverse pathogenic mechanisms. Here, we describe treatment effects achieved by enhancing depression-causing mechanisms in ventral tegmental area (VTA) dopamine (DA) neurons. In a social defeat stress model of depression, depressed (susceptible) mice display hyperactivity of VTA

Cav 2.3 (R-type) calcium channels are critical for mediating anticonvulsive and neuroprotective properties of lamotrigine in vivo.

Maxine Dibué et al.

Epilepsia, 54(9), 1542-1550 (2013-06-19)

Lamotrigine (LTG) is a popular modern antiepileptic drug (AED); however, its mechanism of action has yet to be fully understood, as it is known to modulate many members of several ion channel families. In heterologous systems, LTG inhibits Cav 2.3

View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service